Another Indian company drug (Covid-19 drug) has been approved for corona treatment. The generic pharma company Hetero Labs said that it has been allowed by the Drug Controller General of India (DGCI) to manufacture and market the investigational antiviral drug ‘Remadesiveer’ to treat Covid-19. This drug will be sold in India under the name of ‘Covifor’.
Talking about the price, the final decision has not been taken yet. According to information received from company sources, its price can be Rs 5000-6000. The decision on the price will be taken in the next 3-4 days. It will be an injection that will be sold through the government channel.
Cipla also got permission to make Remadesiveer
The Central Drugs Standard Control Organization (CDSCO) on Saturday approved Hetero Labs as well as Cipla to manufacture and supply Remadesiveer, as per the news published in the Indian Express. Remadesiveer drug Corona treatment is considered to be very successful. American pharma company Gilead Sciences is a patent holder of Remadesiveer. Cipla and Hetero Labs are in a non-exclusive licensing agreement with Gilead Sciences.
This drug can prove to be a game-changer
Dr. B. Partha Saradhi Reddy, Chairman of Hetero Group of Companies, said, ‘In view of the growing Covid-19 cases in India, Covifor (Remadesiveer) can be a game-changer due to its positive clinical results. With strong backward integration capabilities, we can ensure that this product can be delivered instantly to patients across the country. We are ready to ensure sufficient stock to meet the current need. We will continue to work closely with the government and the medical community in the fight against Covid-19. This product has been designed according to the ‘Make in India’ campaign, whose slogan was given by our Honorable Prime Minister. ‘
Covid-19 will be used in severe cases
‘Remadesiveer’ has been approved by DGCI for the treatment of children and adults who are hospitalized with severe symptoms of Covid-19. Covifor (Remadesiveer) will be available in 100 ml gram vial (injectable) which will be given intravenously under the supervision of a doctor in the hospital. The product has been launched under the licensing agreement of Gilead Sciences Inc. to expand the treatment of Covid-19 in low- and middle-income countries.
Drugs for diseases like HIV and AIDS
Hetero has 36 state-of-the-art manufacturing units that are located in important places in the world and are approved by stringent global regulatory authorities. Hetero’s portfolio consists of over 300 products that cover large categories of Remedial categories such as HIV / AIDS, oncology, cardiovascular, neurology, hepatitis, nephrology, urology, diabetes, ophthalmology, hepatology, and immunology, etc. Hetero has a presence in 126 countries in the world and the company is focused on providing affordable medicines to patients around the world.
Glenmark Pharma’s FabiFlu also approved
On Saturday, Glenmark Pharmaceuticals (Glenmark pharma) received approval to launch a generic version of favipiravir for corona treatment. Glenmark has launched the drug by the name FabiFlu. However, this drug has been approved to treat patients with mild symptoms of Covid-19.